Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

101. Cladribine (Mavenclad) - multiple sclerosis

Cladribine (Mavenclad) - multiple sclerosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 22 June 2017 EMA/435731/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report MAVENCLAD International non-proprietary name: cladribine Procedure No. EMEA/H/C/004230/0000 Note Assessment report as adopted (...) Area under the curve BCRP Breast cancer resistant protein, ATP-binding cassette transporter ABCG2 CDMS Clinically Definite Multiple Sclerosis CI Confindence Interval CIS Clinically Isolated Syndrome CL clearance CNS Central Nervous System c max maximum plasma concentration CYP Cytochrome DB Double-Blind DCK Deoxycytidine kinase DMD Disease Modifying Drug EAE Experimental Autoimmune Encephalomyelitis EDSS Expanded Disability Status Scale EMA European Medicines Agency Emax inhibitory maximum exposure

2017 European Medicines Agency - EPARs

102. Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica' Full Text available with Trip Pro

Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica' 28868157 2019 01 15 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica'. 17059 10.1038/scsandc.2017.59 Suthiphosuwan Suradech S St Michael's Hospital, University

2017 Spinal cord series and cases

103. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data Full Text available with Trip Pro

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of this study was to estimate healthcare resource utilization, costs, and relapse

2017 PharmacoEconomics open

104. Perceived Exertion Is Lower When Using a Functional Electrical Stimulation Neuroprosthesis Compared With an Ankle-Foot Orthosis in Persons With Multiple Sclerosis: A Preliminary Study. (Abstract)

Perceived Exertion Is Lower When Using a Functional Electrical Stimulation Neuroprosthesis Compared With an Ankle-Foot Orthosis in Persons With Multiple Sclerosis: A Preliminary Study. This study investigates the direct comparison of energy cost, efficiency, and effort between an ankle-foot orthosis (AFO) and a functional electrical stimulation (FES) device for foot drop in ambulatory patients with multiple sclerosis.Twenty adults (32-74 years old; 55% female) with a diagnosis of multiple (...) -assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to: (1) describe the potential differences between an AFO and FES for the treatment of foot drop in patients with multiple sclerosis, (2) understand the mechanisms and prevalence of foot drop in patients with multiple sclerosis, and (3) recognize the potential benefit of improved perceived exertion found when using FES for the treatment of foot drop

2017 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

105. Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial Full Text available with Trip Pro

Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial To evaluate the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis.It was a three-arm parallel randomized controlled trial study.Outpatient clinic.Patients with multiple sclerosis.Subjects in the intervention groups completed a 12-week program consisted of Cawthorne-Cooksey or Frenkel exercises. The control (...) Balance Scale score increased to 8.9 in the Cawthorne-Cooksey group and 2.3 in the Frenkel group, while it decreased to 1.2 in the control group. When comparing inter-group changes, Berg Balance Scale showed significant improvements in favor of the Cawthorne-Cooksey group after the intervention ( P < 0.05).This study demonstrated that in comparison with Frenkel and the control groups, a program of Cawthorne-Cooksey exercise is more effective in improving balance in patients with multiple sclerosis.

2017 EvidenceUpdates

106. Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment

Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Search Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients (...) and recall of daclizumab (Zinbryta▼) in the EU following reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, in patients with multiple sclerosis. See for more information. Post-publication note; 12 January 2018 The EU-wide review of daclizumab has now concluded. See the for the restricted indication, new precautions for use, and revised monitoring requirements. Review of patients Healthcare professionals should review promptly any patients who are currently

2017 MHRA Drug Safety Update

107. Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis Full Text available with Trip Pro

Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis Regulatory agencies often request prospective, product-specific post-authorization pregnancy exposure registries to monitor safety during pregnancy, even though studies using existing health databases could also be employed.Using multiple sclerosis (MS) as a case study, we evaluated various study designs and data sources previously used to study medication

2017 Drugs - real world outcomes

108. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Full Text available with Trip Pro

Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status.We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability (...) Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients' EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS software

2017 Electronic physician Controlled trial quality: uncertain

109. Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)

Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search (...) will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) July 2017 The current treatment is already licensed in adults, but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod

2017 NIHR Innovation Observatory

110. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial Full Text available with Trip Pro

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy (...) with comprehensive longitudinal cognitive, neuropsychiatric, and HRQoL assessments. We found evidence of a positive effect of simvastatin on frontal lobe function and a physical quality-of-life measure. Although we found no effect of simvastatin on the other outcome measures, these potential effects warrant confirmation and underline the importance of fully assessing cognition and quality of life in progressive multiple sclerosis treatment trials.The Moulton Foundation, the Berkeley Foundation, the Multiple

2017 EvidenceUpdates

111. Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression (Abstract)

Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression This study examined the extent to which patient and trial characteristics moderate the effects of exercise on depressive symptoms among people with multiple sclerosis.Twenty-four effects were derived from 14 articles published before August 2016 located using Google Scholar, MEDLINE, PsycINFO, PubMed, and Web of Science. Trials involved 624 people with multiple sclerosis and included both (...) with multiple sclerosis. Exercise-induced improvements in fatigue significantly moderated exercise effects on depressive symptoms. Future trials may benefit from focusing on using exercise to concurrently improve depressive symptoms and fatigue as a symptom cluster.Copyright © 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

2017 EvidenceUpdates

112. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]

[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe

2017 Health Technology Assessment (HTA) Database.

113. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. Full Text available with Trip Pro

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis.During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms within the previous 180 (...) days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first. The primary outcome was conversion to multiple sclerosis (diagnosed on the basis of the 2005 McDonald criteria) within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within 24 months after

2017 NEJM Controlled trial quality: predicted high

114. Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Full Text available with Trip Pro

Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy - GOV.UK GOV.UK uses cookies to make the site simpler. Search Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Healthcare professionals should report any suspected adverse effects relating to fingolimod (Gilenya▼) or other treatments for multiple sclerosis, including (...) suspected adverse effects occurring after discontinuation, via the Yellow Card Scheme. Published 24 April 2017 From: Therapeutic area: We are aware of two recently published articles describing a suspected rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected for that patient prior to discontinuation or treatment change) in patients with multiple sclerosis after treatment with fingolimod (Gilenya▼) was stopped, some of whom were switched to other treatments

2017 MHRA Drug Safety Update

115. Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis

Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis Ocrevus (ocrelizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Ocrevus (ocrelizumab) Injection Ocrevus Company: Genentech, Inc. Application No.: 761053 Approval Date: 03/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

116. Daclizumab for treating relapsing?remitting multiple sclerosis

Daclizumab for treating relapsing?remitting multiple sclerosis Daclizumab for treating relapsing–remitting multiple sclerosis | Guidance | NICE Daclizumab for treating relapsing–remitting multiple sclerosis Technology appraisal guidance [TA441] Published date: 26 April 2017 Guidance This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s . Explore © NICE [year]. All rights reserved. Subject to .

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

117. Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions Full Text available with Trip Pro

Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. MRI has an important role in early diagnosis of MS within diagnostic criteria.To determine the diagnostic value of the double inversion recovery (DIR) sequence in detection of brain MS lesions.In this cross-sectional study, 55 patients were admitted

2017 Electronic physician

118. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Full Text available with Trip Pro

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in the mid-1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack. As most (...) drugs according to their benefit and safety;3. to estimate the benefit and safety of disease-modifying drugs that have been evaluated in all studies (randomised or non-randomised) for treatment started after a first attack ('early treatment') compared with treatment started after a second attack or at another later time point ('delayed treatment').We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, MEDLINE, Embase, CINAHL, LILACS, clinicaltrials.gov

2017 Cochrane

119. Multiple Sclerosis

Multiple Sclerosis ©Institute for Clinical and Economic Review, 2017 Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Final Evidence Report March 6, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Final Evidence Report – DMTs for RRMS and PPMS ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group Jeffrey A. Tice, MD Professor of Medicine University of California (...) 148 Appendix E. Comparative Value Supplemental Information 166 Appendix F. Patient Survey Questions 204 Appendix G. Public Comments 210 Appendix H. Conflict of Interest Disclosures 216 ©Institute for Clinical and Economic Review, 2017 Page vi Final Evidence Report – DMTs for RRMS and PPMS List of Acronyms Used in this Report AHRQ Agency for Healthcare Research and Quality BID Twice daily CDMS Clinically definite multiple sclerosis CI Confidence interval CIS Clinically isolated syndrome CNS Central

2017 California Technology Assessment Forum

120. Portable neuromodulation stimulator for multiple sclerosis

Portable neuromodulation stimulator for multiple sclerosis Portable neuromodulation stimulator for multiple sclerosis | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced (...) as required for our stakeholders. > > > Portable neuromodulation stimulator for multiple sclerosis Portable neuromodulation stimulator for multiple sclerosis March 2017 The Portable Neuromodulation Stimulator or PoNS™, developed by Helius Medical Technologies, is a non-invasive device that is designed to deliver neurostimulation through the tongue to improve balance and gait in patients with advanced multiple sclerosis (MS). The device is intended to be used as part of targeted functional therapy called

2017 NIHR Innovation Observatory